Earnings summaries and quarterly performance for MACROGENICS.
Executive leadership at MACROGENICS.
Eric Risser
Detailed
President and Chief Executive Officer
CEO
BS
Beth Smith
Detailed
Vice President, Controller and Treasurer
EB
Ezio Bonvini
Detailed
Senior Vice President, Research and Chief Scientific Officer
JK
James Karrels
Detailed
Senior Vice President, Chief Financial Officer and Corporate Secretary
JP
Jeffrey Peters
Detailed
Senior Vice President, General Counsel and Corporate Compliance Officer
SE
Stephen Eck
Detailed
Senior Vice President, Clinical Development and Chief Medical Officer
TS
Thomas Spitznagel
Detailed
Senior Vice President, Technical Operations
Board of directors at MACROGENICS.
DS
David Stump
Detailed
Director
EH
Edward Hurwitz
Detailed
Director
FO
Federica O'Brien
Detailed
Director
JS
Jay Siegel
Detailed
Director
KF
Karen Ferrante
Detailed
Director
ML
Margaret Liu
Detailed
Director
MC
Meenu Chhabra Karson
Detailed
Director
SJ
Scott Jackson
Detailed
Director
SK
Scott Koenig
Detailed
Director
WH
William Heiden
Detailed
Chair of the Board
Research analysts who have asked questions during MACROGENICS earnings calls.
Jonathan Miller
Evercore ISI
4 questions for MGNX
Also covers: APLS, ARVN, ATRA +8 more
Mayank Mamtani
B. Riley Securities
4 questions for MGNX
Also covers: AGEN, ALT, ARWR +18 more
PL
Peter Lawson
Barclays PLC
4 questions for MGNX
Also covers: ADAP, ARVN, BPMC +15 more
ST
Silvan Tuerkcan
Citizens JMP
4 questions for MGNX
Also covers: CLLS, EXEL, NTLA +2 more
ED
Etzer Darout
BMO Capital Markets
3 questions for MGNX
Also covers: ARVN, CTMX, EXEL +5 more
JC
Jonathan Chang
Leerink Partners
3 questions for MGNX
Also covers: ADAP, GMAB, IMCR +10 more
SW
Stephen Willey
Stifel Financial Corp.
3 questions for MGNX
Also covers: ABCL, CELC, CGEN +10 more
AM
Ashiq Mubarack
Citigroup Inc.
2 questions for MGNX
Also covers: IPHA, MRSN, RAIN +1 more
KP
Kaveri Pohlman
BTIG, LLC
2 questions for MGNX
Also covers: MDGL, NUVB, RCUS +3 more
KG
Kelsey Goodwin
Guggenheim Securities
2 questions for MGNX
Also covers: TSVT, URGN
SW
Stephen Willey
Stifel
2 questions for MGNX
Also covers: ABCL, ABEO, CGEN +7 more
JM
John Miller
Evercore ISI
1 question for MGNX
Also covers: ZYME
TB
Tara Bancroft
TD Cowen
1 question for MGNX
Also covers: ADVM, CELC, DAWN +10 more
YN
Yigal Nochomovitz
Citigroup Inc.
1 question for MGNX
Also covers: ALDX, APLS, ARCT +22 more
Recent press releases and 8-K filings for MGNX.
Agenus Provides Pipeline and Financial Updates
MGNX
New Projects/Investments
Guidance Update
- Agenus discontinued lorigerlimab in prostate cancer after interim results from the LORIKEET study did not meet targeted thresholds for differentiation. The company will now focus on pursuing opportunities for lorigerlimab in ovarian and clear cell gynecological cancers through the LINET study.
- The LINET study, exploring lorigerlimab in gynecologic indications, is a Simon two-stage study that has recently initiated and is ramping up nicely, with updates expected around middle of next year (2026).
- The company is advancing its Antibody-Drug Conjugate (ADC) pipeline, with the B7H3 asset (O26) now in expansion cohorts and the ADAM9 asset (O28) moving through dose escalation. Clinical data for these first two ADCs is anticipated next year (2026).
- Agenus reported a Q3 cash balance of $146 million. Including subsequent milestones from collaborations with Gilead and Sanofi, the company has extended its cash runway guidance into late 2027.
Dec 4, 2025, 12:55 PM
MGNX Provides Updates on Pipeline and Cash Runway
MGNX
New Projects/Investments
Guidance Update
- MGNX discontinued lorigerlimab in prostate cancer due to interim results from the LORIKEET study not meeting the targeted threshold for differentiation, and will instead focus on ovarian and clear cell gynecological cancers with the LINET study.
- The company is advancing its ADC pipeline, including a B7H3 asset (furthest advanced, with two expansion cohorts enrolling) and a second-generation ADAM9 molecule (O28), both utilizing the Synaffix platform.
- MGNX reported a Q3 cash balance of $146 million, which, with additional milestones from Gilead and Sanofi, extends their cash runway guidance into late 2027.
- Clinical data for the first two ADCs is expected to start being seen next year, with updates on the LINET program anticipated in mid-next year.
Dec 4, 2025, 12:55 PM
MacroGenics CEO Outlines Strategic Imperatives and Pipeline Updates
MGNX
CEO Change
Guidance Update
New Projects/Investments
- MacroGenics' new CEO, Eric Risser, outlined six strategic imperatives, including advancing ADC programs, new INDs, corporate partnering, and strengthening the financial position.
- The LOWERKEY trial for lorigerlimab (CTLA-4 PD-1 bispecific) in prostate cancer was discontinued due to not meeting its primary endpoint, while the Linet study in gynecological malignancies remains active, with a clinical update expected mid-2026.
- The company is advancing its ADC pipeline, with the B7H3 ADC (MGC018) having selected a dose for expansion and initiated two solid tumor cohorts, and the ADAM9 ADC (MGC028) in dose escalation. An IND for a new undisclosed ADC, MGC030, is expected in 2026.
- MacroGenics received $75 million in Q4 2025 from collaborations with Gilead and Sanofi, contributing to over $600 million in non-dilutive capital over the last three years. Cash and cash equivalents were $146 million as of September 30, 2025, extending the cash runway into late 2027.
Nov 13, 2025, 9:00 PM
MacroGenics Provides Financial Update and Strategic Priorities for 2025-2026
MGNX
Guidance Update
New Projects/Investments
- MacroGenics reported $146.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with a cash runway guidance into late 2027. This guidance includes $75.0 million in expected partnering payments from Sanofi and Gilead subsequent to September 30, 2025.
- The company's strategic priorities for 2025-2026 include determining the development path for lorigerlimab, advancing MGC026 and MGC028 to assess clinical proof-of-concept, and completing the IND application for MGC030.
- The lorigerlimab program, a PD-1 × CTLA-4 DART molecule, is currently in an ongoing LINNET Phase 2 study for ovarian cancer, with an update anticipated by mid-2026. It represents a potential novel approach for Platinum Resistant Ovarian Cancer and Clear Cell Gynecological Cancers, with >$2 billion in forecast peak sales.
Nov 12, 2025, 11:00 PM
MacroGenics Reports Q3 2025 Financial Results and Strategic Pipeline Revisions
MGNX
Earnings
Guidance Update
New Projects/Investments
- MacroGenics reported total revenue of $72.8 million and net income of $16.8 million for the third quarter ended September 30, 2025.
- The company's cash, cash equivalents, and marketable securities were $146.4 million as of September 30, 2025, and its cash runway guidance was extended into late 2027.
- MacroGenics secured an additional $75 million in partnering proceeds from Sanofi and Gilead, expected in Q4 2025, and licensed a new preclinical program to Gilead.
- The company decided to discontinue further development of lorigerlimab in prostate cancer based on interim data from the LORIKEET study, but will continue its development in ovarian and other gynecologic cancers.
Nov 12, 2025, 9:04 PM
MacroGenics Provides Pipeline and Financial Update at TD Cowen Conference
MGNX
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- MacroGenics, an immunotherapeutics company, reported $200 million in cash as of its third-quarter earnings, providing funding into 2026.
- The company has a diverse pipeline, including three FDA-approved monoclonal antibodies and several clinical-stage assets such as vobramitamab duocarmazine (ADC), lorigerlimab (PD-1 CTLA-4), and MGC026 (next-generation B7-H3 ADC).
- MacroGenics has secured $475 million in non-dilutive capital from partnerships and milestone payments over the past 2.5 to 3 years.
- Partnered asset Zynyz (with Incyte) has generated $365 million to date, with potential for hundreds of millions in future milestones and a 15%-24% royalty. Zynyz is approved in Merkel cell cancer and anticipates approval in anal cancer in 2025.
- Enrollment for the LORIKEET study of lorigerlimab in prostate cancer was completed in December, with a readout expected this year.
Mar 5, 2025, 3:30 PM
Quarterly earnings call transcripts for MACROGENICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more